• MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial. 

  Anandappa, G; Lampis, A; Cunningham, D; Khan, KH; Kouvelakis, K; Vlachogiannis, G; Hedayat, S; Tunariu, N; Rao, S; Watkins, D; Starling, N; Braconi, C; Darvish Damavandi, M; Lote, H; Thomas, J; Peckitt, C; Kalaitzaki, E; Khan, N; Fotiadis, N; Rugge, M; Begum, R; Rana, I; Bryant, A; Hahne, JC; Chau, I; Fassan, M; Valeri, N (2019-04-05)

  PURPOSE: Anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibodies (mABs) are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumour location (sidedness) are predictive ...
• miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. 

  Fassan, M; Cui, R; Gasparini, P; Mescoli, C; Guzzardo, V; Vicentini, C; Munari, G; Loupakis, F; Lonardi, S; Braconi, C; Scarpa, M; D'Angelo, E; Pucciarelli, S; Angriman, I; Agostini, M; D'Incá, R; Farinati, F; Gafà, R; Lanza, G; Frankel, WL; Croce, CM; Valeri, N; Rugge, M (2019-02)

  miR-224 has recently emerged as a driver oncomiR in sporadic colorectal carcinogenesis, but its pathogenetic role is still controversial. A large phenotypical and molecularly characterized series of preinvasive and invasive ...
• Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. 

  Khan, K; Rane, JK; Cunningham, D; Rao, S; Watkins, D; Starling, N; Kalaitzaki, E; Forster, M; Braconi, C; Valeri, N; Gerlinger, M; Chau, I (2019-03)

  BACKGROUND: Gastrointestinal (GI) cancer patients may not be considered for therapy with fluoropyrimidines (FPs) because of previous cardiovascular (CV) toxicity or preexisting risk factors; such patients may benefit from ...
• Cut-and-Run: A Distinct Mechanism by which V(D)J Recombination Causes Genome Instability. 

  Kirkham, CM; Scott, JNF; Wang, X; Smith, AL; Kupinski, AP; Ford, AM; Westhead, DR; Stockley, PG; Tuma, R; Boyes, J (2019-03-18)

  V(D)J recombination is essential to generate antigen receptor diversity but is also a potent cause of genome instability. Many chromosome alterations that result from aberrant V(D)J recombination involve breaks at single ...
• Elevated platelet count appears to be causally associated with increased risk of lung cancer: A Mendelian randomization analysis. 

  Zhu, Y; Wei, Y; Zhang, R; Dong, X; Shen, S; Zhao, Y; Bai, J; Albanes, D; Caporaso, NE; Landi, MT; Zhu, B; Chanock, SJ; Gu, F; Lam, S; Tsao, M-S; Shepherd, FA; Tardon, A; Fernández-Somoano, A; Fernandez-Tardon, G; Chen, C; Barnett, MJ; Doherty, J; Bojesen, SE; Johansson, M; Brennan, P; McKay, JD; Carreras-Torres, R; Muley, T; Risch, A; Wichmann, H-E; Bickeboeller, H; Rosenberger, A; Rennert, G; Saliba, W; Arnold, SM; Field, JK; Davies, MPA; Marcus, MW; Wu, X; Ye, Y; Le Marchand, L; Wilkens, LR; Melander, O; Manjer, J; Brunnström, H; Hung, RJ; Liu, G; Brhane, Y; Kachuri, L; Andrew, AS; Duell, EJ; Kiemeney, LA; van der Heijden, EHFM; Haugen, A; Zienolddiny, S; Skaug, V; Grankvist, K; Johansson, M; Woll, PJ; Cox, A; Taylor, F; Teare, DM; Lazarus, P; Schabath, MB; Aldrich, MC; Houlston, RS; McLaughlin, J; Stevens, VL; Shen, H; Hu, Z; Dai, J; Amos, CI; Han, Y; Zhu, D; Goodman, GE; Chen, F; Christiani, DC (2019-01-30)

  BACKGROUND: Platelets are a critical element in coagulation and inflammation, and activated platelets are linked to cancer risk through diverse mechanisms. However, a causal relationship between platelets and risk of lung ...
• Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma. 

  Fultang, L; Gamble, LD; Gneo, L; Berry, AM; Egan, SA; De Bie, F; Yogev, O; Eden, GL; Booth, S; Brownhill, S; Vardon, A; McConville, CM; Cheng, PN; Norris, MD; Etchevers, HC; Murray, J; Ziegler, DS; Chesler, L; Schmidt, R; Burchill, SA; Haber, M; De Santo, C; Mussai, F (2019-02-01)

  Neuroblastoma is the most common childhood solid tumor, yet the prognosis for high-risk disease remains poor. We demonstrate here that arginase 2 (ARG2) drives neuroblastoma cell proliferation via regulation of arginine ...
• Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. 

  Amirian, ES; Ostrom, QT; Armstrong, GN; Lai, RK; Gu, X; Jacobs, DI; Jalali, A; Claus, EB; Barnholtz-Sloan, JS; Il'yasova, D; Schildkraut, JM; Ali-Osman, F; Sadetzki, S; Jenkins, RB; Lachance, DH; Olson, SH; Bernstein, JL; Merrell, RT; Wrensch, MR; Johansen, C; Houlston, RS; Scheurer, ME; Shete, S; Amos, CI; Melin, B; Bondy, ML (2019-03)

  BACKGROUND: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the ...
• Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. 

  Zeid, R; Lawlor, MA; Poon, E; Reyes, JM; Fulciniti, M; Lopez, MA; Scott, TG; Nabet, B; Erb, MA; Winter, GE; Jacobson, Z; Polaski, DR; Karlin, KL; Hirsch, RA; Munshi, NP; Westbrook, TF; Chesler, L; Lin, CY; Bradner, JE (2018-04)

  Amplification of the locus encoding the oncogenic transcription factor MYCN is a defining feature of high-risk neuroblastoma. Here we present the first dynamic chromatin and transcriptional landscape of MYCN perturbation ...
• Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. 

  Dolman, ME; Poon, E; Ebus, ME; den Hartog, IJ; van Noesel, CJ; Jamin, Y; Hallsworth, A; Robinson, SP; Petrie, K; Sparidans, RW; Kok, RJ; Versteeg, R; Caron, HN; Chesler, L; Molenaar, JJ (2015-11)

  MYCN-dependent neuroblastomas have low cure rates with current multimodal treatment regimens and novel therapeutic drugs are therefore urgently needed. In previous preclinical studies, we have shown that targeted inhibition ...
• CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. 

  Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; Woolston, A; Spain, G; von Loga, K; Challoner, B; Patel, R; Ranes, M; Swain, A; Thomas, J; Bryant, A; Saffery, C; Fotiadis, N; Guettler, S; Mansfield, D; Melcher, A; Powles, T; Rao, S; Watkins, D; Chau, I; Matthews, N; Wallberg, F; Starling, N; Cunningham, D; Gerlinger, M (2019-04-15)

  BACKGROUND: The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high ...
• Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach. 

  Leal, MF; Haynes, BP; MacNeill, FA; Dodson, A; Dowsett, M (2019-02-22)

  PURPOSE: We evaluated whether multiplex protein quantification using antibody bar-coding with photocleavable oligonucleotides (NanoString) can be applied to evaluate protein expression in breast cancer FFPE specimens. We ...
• Telomere elongation through hTERT immortalization leads to chromosome repositioning in control cells and genomic instability in Hutchinson-Gilford progeria syndrome fibroblasts, expressing a novel SUN1 isoform. 

  Bikkul, MU; Faragher, RGA; Worthington, G; Meinke, P; Kerr, ARW; Sammy, A; Riyahi, K; Horton, D; Schirmer, EC; Hubank, M; Kill, IR; Anderson, RM; Slijepcevic, P; Makarov, E; Bridger, JM (2019-06)

  Immortalizing primary cells with human telomerase reverse transcriptase (hTERT) has been common practice to enable primary cells to be of extended use in the laboratory because they avoid replicative senescence. Studying ...
• Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. 

  Allin, DM; Shaikh, R; Carter, P; Thway, K; Sharabiani, MTA; Gonzales-de-Castro, D; O'Leary, B; Garcia-Murillas, I; Bhide, S; Hubank, M; Harrington, K; Kim, D; Newbold, K (2018-11)

  BACKGROUND: Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in ...
• MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Anti-angiogenic Treatment. 

  Zormpas-Petridis, K; Jerome, NP; Blackledge, MD; Carceller, F; Poon, E; Clarke, M; McErlean, CM; Barone, G; Koers, A; Vaidya, SJ; Marshall, LV; Pearson, ADJ; Moreno, L; Anderson, J; Sebire, N; McHugh, K; Koh, D-M; Yuan, Y; Chesler, L; Robinson, SP; Jamin, Y (2019-03-15)

  Childhood neuroblastoma is a hypervascular tumor of neural origin for which antiangiogenic drugs are currently being evaluated; however, predictive biomarkers of treatment response, crucial for successful delivery of ...
• Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients. 

  Zheng, G; Chattopadhyay, S; Sud, A; Sundquist, K; Sundquist, J; Försti, A; Houlston, RS; Hemminki, A; Hemminki, K (2019-03-26)
• Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. 

  Watts, E; Heidenreich, D; Tucker, E; Raab, M; Strebhardt, K; Chesler, L; Knapp, S; Bellenie, B; Hoelder, S (2019-03-14)

  Concomitant inhibition of anaplastic lymphoma kinase (ALK) and bromodomain-4 (BRD4) is a potential therapeutic strategy for targeting two key oncogenic drivers that co-segregate in a significant fraction of high-risk ...
• Three-dimensional cardiovascular imaging-genetics: a mass univariate framework. 

  Biffi, C; de Marvao, A; Attard, MI; Dawes, TJW; Whiffin, N; Bai, W; Shi, W; Francis, C; Meyer, H; Buchan, R; Cook, SA; Rueckert, D; O'Regan, DP (2018-01-01)

  Motivation: Left ventricular (LV) hypertrophy is a strong predictor of cardiovascular outcomes, but its genetic regulation remains largely unexplained. Conventional phenotyping relies on manual calculation of LV mass and ...
• Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. 

  Dowsett, M; Turner, N (2019-03-20)
• Evolutionary dynamics of residual disease in human glioblastoma. 

  Spiteri, I; Caravagna, G; Cresswell, GD; Vatsiou, A; Nichol, D; Acar, A; Ermini, L; Chkhaidze, K; Werner, B; Mair, R; Brognaro, E; Verhaak, RGW; Sanguinetti, G; Piccirillo, SGM; Watts, C; Sottoriva, A (2019-03-01)

  BACKGROUND: Glioblastoma is the most common and aggressive adult brain malignancy against which conventional surgery and chemoradiation provide limited benefit. Even when a good treatment response is obtained, recurrence ...
• Challenges to curing primary brain tumours. 

  Aldape, K; Brindle, KM; Chesler, L; Chopra, R; Gajjar, A; Gilbert, MR; Gottardo, N; Gutmann, DH; Hargrave, D; Holland, EC; Jones, DTW; Joyce, JA; Kearns, P; Kieran, MW; Mellinghoff, IK; Merchant, M; Pfister, SM; Pollard, SM; Ramaswamy, V; Rich, JN; Robinson, GW; Rowitch, DH; Sampson, JH; Taylor, MD; Workman, P; Gilbertson, RJ (2019-02-07)

  Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic ...

View more